There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

Bushnell also noted the ability of GLP-1 receptor agonists to decrease blood pressure and to decrease plaque formation associated with atherosclerosis, which is a risk factor for heart attack and ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...